BRPI0516128A - uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica - Google Patents

uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica

Info

Publication number
BRPI0516128A
BRPI0516128A BRPI0516128-2A BRPI0516128A BRPI0516128A BR PI0516128 A BRPI0516128 A BR PI0516128A BR PI0516128 A BRPI0516128 A BR PI0516128A BR PI0516128 A BRPI0516128 A BR PI0516128A
Authority
BR
Brazil
Prior art keywords
diastolic
prevention
treatment
heart failure
renin inhibitors
Prior art date
Application number
BRPI0516128-2A
Other languages
English (en)
Inventor
David Louis Feldman
Friedrich Cameron Luft
Dominik Nicolas Mueller
Randy Lee Webb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35789048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0516128(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0516128A publication Critical patent/BRPI0516128A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

USO DE INIBIDORES DE RENINA PARA A PREVENçãO OU TRATAMENTO DE DISFUNçãO DIASTóLICA OU INSUFICIêNCIA CARDìACA DIASTóLICA. A presente invenção fornece o uso de uma quantidade terapeuticamente efetiva de um inibidor de renina, ou sal farmaceuticamente aceitável deste, sozinho ou em combinação com (i) um inibidor de ACE ou um sal farmaceuticamente aceitável deste; ou (11) um bloqueador de receptor de angiotensina 11 ou um sal farmaceuticamente aceitável deste, para a fabricação de um medicamento para a prevenção de, progressão retardada de predisposição a, ou o tratamento de disfunção diastólica ou insuficiência cardíaca diastólica em um animal de sangue quente.
BRPI0516128-2A 2004-10-08 2005-10-06 uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica BRPI0516128A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61720204P 2004-10-08 2004-10-08
US66789905P 2005-04-01 2005-04-01
PCT/US2005/035914 WO2006041974A1 (en) 2004-10-08 2005-10-06 Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure

Publications (1)

Publication Number Publication Date
BRPI0516128A true BRPI0516128A (pt) 2008-08-26

Family

ID=35789048

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516128-2A BRPI0516128A (pt) 2004-10-08 2005-10-06 uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica

Country Status (15)

Country Link
US (2) US20080085914A1 (pt)
EP (2) EP2248520A3 (pt)
JP (1) JP2008515903A (pt)
KR (2) KR20070101843A (pt)
CN (1) CN101102755B (pt)
AT (1) ATE551052T1 (pt)
AU (2) AU2005294318A1 (pt)
BR (1) BRPI0516128A (pt)
CA (1) CA2580862A1 (pt)
ES (1) ES2384637T3 (pt)
MX (1) MX2007004020A (pt)
PL (1) PL1799199T3 (pt)
PT (1) PT1799199E (pt)
RU (1) RU2407523C2 (pt)
WO (1) WO2006041974A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
MX2009010428A (es) * 2007-03-27 2009-12-01 Calpis Co Ltd Agente profilactico para insuficiencia renal.
US20100209480A1 (en) * 2007-09-28 2010-08-19 Ralf Altenburger Galenical formulations of organic compounds
PT2205279E (pt) * 2007-09-28 2011-07-11 Novartis Ag Associação farmacêutica de aliscireno e valsartan
US20110287100A1 (en) * 2009-01-28 2011-11-24 Sabine Desset-Brethes Galenic Formulations of Organic Compounds
EP2340820A1 (en) * 2009-12-16 2011-07-06 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2216020A1 (en) * 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
WO2010089105A2 (en) * 2009-02-05 2010-08-12 Krka, Tovarna Zdravil, D.D., Novo Mesto Moisture-activated granulation process
WO2011001440A1 (en) * 2009-07-03 2011-01-06 Hetero Research Foundation Pharmaceutical compositions of valsartan
EP2382969A1 (en) * 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DK0403159T3 (da) 1989-06-14 2000-08-14 Smithkline Beecham Corp Imidazolylalkensyrer
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
TW201738B (pt) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DK0527879T3 (da) * 1990-05-11 1997-07-14 Pfizer Synergistiske terapeutiske præparater og fremgangsmåder.
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
TW226375B (pt) 1991-10-24 1994-07-11 American Home Prod
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
CA2490811A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
CN1906163A (zh) * 2003-11-26 2007-01-31 诺瓦提斯公司 作为肾素抑制剂的4－苯基哌啶衍生物
JP4884230B2 (ja) * 2003-11-26 2012-02-29 ノバルティス アーゲー 有機化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
CN101102755A (zh) 2008-01-09
JP2008515903A (ja) 2008-05-15
MX2007004020A (es) 2007-05-24
EP1799199B1 (en) 2012-03-28
AU2005294318A1 (en) 2006-04-20
PT1799199E (pt) 2012-07-03
KR20130048281A (ko) 2013-05-09
US20080085914A1 (en) 2008-04-10
KR20070101843A (ko) 2007-10-17
WO2006041974A1 (en) 2006-04-20
EP2248520A3 (en) 2010-11-17
EP1799199A1 (en) 2007-06-27
EP2248520A2 (en) 2010-11-10
CA2580862A1 (en) 2006-04-20
ATE551052T1 (de) 2012-04-15
CN101102755B (zh) 2013-01-02
AU2010200833A1 (en) 2010-04-01
PL1799199T3 (pl) 2012-09-28
RU2007116863A (ru) 2008-11-20
AU2010200833B2 (en) 2011-07-14
RU2407523C2 (ru) 2010-12-27
US20130196977A1 (en) 2013-08-01
ES2384637T3 (es) 2012-07-10

Similar Documents

Publication Publication Date Title
WO2007149797A3 (en) Use of organic compounds
DK1725544T3 (da) 3-[4-Heterocyclyl-1,2,3-triazol-1-yl]-N-aryl-benzamider som inhibitorer for produktion af cytokiner til behandling af kroniske inflammatoriske sygdomme
CL2007003594A1 (es) Compuestos derivados de heterociclos condensados de nitrogeno, inhibidores de transcriptasa inversa no nucleosidicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sida.
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
LTC2805723I2 (lt) Kladribino režimas, skirtas išsėtinei sklerozei gydyti
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
ZA200709072B (en) Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
BRPI0516128A (pt) uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
IL180495A0 (en) Benzyltriazolone compounds as nin-nucleoside reverse transcriptase inhibitors
EP1900362A3 (en) Alfa-aminoamide derivatives useful in the treatment of addictive disorders
IL178100A0 (en) 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
CL2007001747A1 (es) Compuestos derivados de aril y heteroaril-etil-acilguanidina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y prevencion de la hipertension, insuficiencia cardiaca y afecciones renales entre otras.
WO2004098599A3 (en) Proton pump inhibitors for the treatment of lower abdominal disorders
EP2366393A3 (en) Roflumilast for the treatment of pulmonary hypertension
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 9A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2293 DE 16/12/2014.